Nothing Special   »   [go: up one dir, main page]

CA2339638A1 - Composes monocycliques presentant une fonction antagoniste de nk-2, et compositions a base de ces composes - Google Patents

Composes monocycliques presentant une fonction antagoniste de nk-2, et compositions a base de ces composes Download PDF

Info

Publication number
CA2339638A1
CA2339638A1 CA002339638A CA2339638A CA2339638A1 CA 2339638 A1 CA2339638 A1 CA 2339638A1 CA 002339638 A CA002339638 A CA 002339638A CA 2339638 A CA2339638 A CA 2339638A CA 2339638 A1 CA2339638 A1 CA 2339638A1
Authority
CA
Canada
Prior art keywords
trp
suc
cyclo
phe
ch2nh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002339638A
Other languages
English (en)
Inventor
Maria Altamura
Marco Criscuoli
Antonio Guidi
Enzo Perrotta
Carlo Alberto Maggi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Menarini Ricerche SpA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2339638A1 publication Critical patent/CA2339638A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des composés représentés par la formule générale (I) et ceux de leurs sels pharmaceutiquement admis qui présentent une action antagoniste sur le récepteur NK2. L'invention concerne également l'élaboration de ces composés ainsi que des préparations pharmaceutiques à base de tels composés.
CA002339638A 1998-08-05 1999-07-30 Composes monocycliques presentant une fonction antagoniste de nk-2, et compositions a base de ces composes Abandoned CA2339638A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITFI98A000186 1998-08-05
IT1998FI000186A IT1304888B1 (it) 1998-08-05 1998-08-05 Composti monociclici ad azione nk-2 antagonista e formulazioni che licontengono
PCT/EP1999/005459 WO2000008046A1 (fr) 1998-08-05 1999-07-30 Composes monocycliques presentant une fonction antagoniste de nk-2, et compositions a base de ces composes

Publications (1)

Publication Number Publication Date
CA2339638A1 true CA2339638A1 (fr) 2000-02-17

Family

ID=11352646

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002339638A Abandoned CA2339638A1 (fr) 1998-08-05 1999-07-30 Composes monocycliques presentant une fonction antagoniste de nk-2, et compositions a base de ces composes

Country Status (11)

Country Link
EP (1) EP1102789A1 (fr)
JP (1) JP2002522450A (fr)
AR (1) AR021751A1 (fr)
AU (1) AU5507999A (fr)
CA (1) CA2339638A1 (fr)
CO (1) CO5080789A1 (fr)
IT (1) IT1304888B1 (fr)
PE (1) PE20001002A1 (fr)
TR (1) TR200100354T2 (fr)
TW (1) TW491857B (fr)
WO (1) WO2000008046A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1307809B1 (it) * 1999-10-21 2001-11-19 Menarini Ricerche Spa Composti monociclici basici ad azione nk-2 antagonista, processi difabbricazione e formulazioni che li contengono.
PL217630B1 (pl) 2003-04-24 2014-08-29 Incyte Corp Pochodne azaspiroalkanów, kompozycja farmaceutyczna oraz zastosowanie związku
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703034A (en) * 1986-04-28 1987-10-27 Merck & Co., Inc. Novel cyclic tetrapeptide
EP0606222A1 (fr) * 1991-08-08 1994-07-20 A. Menarini Industrie Farmaceutiche Riunite S.R.L. Hexapeptides cycliques servant d'antagonistes de tachyquinines, leur preparation, et compositions pharmaceutiques les contenant
EP0528312B1 (fr) * 1991-08-13 1997-07-16 Takeda Chemical Industries, Ltd. Peptides cycliques et leur utilisation
IT1277835B1 (it) * 1995-03-13 1997-11-12 Menarini Farma Ind Composti biciclici, loro preparazione ed uso in composizioni farmaceutiche
IT1291776B1 (it) * 1997-02-07 1999-01-21 Menarini Ricerche Spa Composti monociclici a quattro residui bifunzionali, aventi azione nk-2 antagonista

Also Published As

Publication number Publication date
EP1102789A1 (fr) 2001-05-30
TW491857B (en) 2002-06-21
JP2002522450A (ja) 2002-07-23
AR021751A1 (es) 2002-08-07
IT1304888B1 (it) 2001-04-05
TR200100354T2 (tr) 2001-05-21
ITFI980186A1 (it) 2000-02-05
PE20001002A1 (es) 2000-10-16
WO2000008046A1 (fr) 2000-02-17
CO5080789A1 (es) 2001-09-25
AU5507999A (en) 2000-02-28

Similar Documents

Publication Publication Date Title
EP0934950B1 (fr) Derivé de tetrapeptide
US4472305A (en) Hexapeptide amides
WO2004020462A1 (fr) Antagoniste de cxcr4 et son utilisation
FI70228C (fi) Foerfarande foer framstaellning av en enkefalin-analog-peptid
WO1999009053A1 (fr) Derives de phenylethylamine
IE921689A1 (en) Terminally modified tri-, tetra- and pentapeptide¹anaphylatoxin receptor ligands
WO1997010836A1 (fr) Peptides et mimes de peptides inhibiteurs de l'action oncogenique de la p21 ras
US5811400A (en) Peptide derivatives with δ opioid receptor antagonist or mixed μ agδ antagonist effects
EP1107981B1 (fr) Synthese des analogues peptidiques cycliques a systeme cyclique modifie
JPH06234790A (ja) 新規テトラペプチドアミド誘導体
EP1224210B1 (fr) Composes monocycliques basiques presentant une activite antagoniste de nk2, procedes de fabrication, et formulation contenant ces composes
HU185229B (en) Process for preparing pharmaceutically active peptides and acetates thereof
CA2339638A1 (fr) Composes monocycliques presentant une fonction antagoniste de nk-2, et compositions a base de ces composes
JP7032808B2 (ja) ペプチドもしくはその薬学的に許容される塩、またはそれらのプロドラッグ
US6780968B1 (en) Monocyclic compounds with four bifunctional residues having NK-2 antagonist action
JP4467985B2 (ja) 新規なオピオイド誘導体
JP2020059663A (ja) ペプチドもしくはその薬学的に許容される塩、またはそれらのプロドラッグ
JP2000044595A (ja) フェネチルアミン誘導体
WO2022009698A1 (fr) Peptide et complexe le comprenant
Ballet et al. Bradykinin analogs containing the 4‐amino‐2‐benzazepin‐3‐one scaffold at the C‐terminus
CA1131217A (fr) Peptides psycho-pharmacologiques
JPWO2002102833A1 (ja) 新規エンドモルフィン誘導体
JP2001122895A (ja) 新規なオピオイドペプチド誘導体
JP3810129B2 (ja) 新規なフエネチルアミド誘導体
WO1995030694A1 (fr) Nouveaux analogues de peptides opioides presentant des proprietes mixtes d'agonistes mu et d'antagonistes delta

Legal Events

Date Code Title Description
FZDE Dead